CAS
IMCR icon

Coppell Advisory Solutions’s Immunocore IMCR Stock Holding History

Coppell Advisory Solutions’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-617
Closed -$19.4K – 2033
2024
Q3 		$19.4K Buy
+617
New +$22.4K ﹤0.01% 892

Other funds holding IMCR

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Coppell Advisory Solutions's IMCR Position: Q4 2024 in Review

Coppell Advisory Solutions sold out of Immunocore (IMCR) in Q4 2024, closing a stake of 617 shares — an estimated $19.4K sold.

Coppell Advisory Solutions first reported a position in IMCR in Q3 2024 and held it in 1 quarter. The position peaked at $19.4K in Q3 2024. 115 funds tracked by Wall St. Rank hold IMCR as of Q4 2024.

  • Coppell Advisory Solutions reported no remaining Immunocore position as of Q4 2024 after selling out during the quarter.
  • Coppell Advisory Solutions sold 617 Immunocore shares in Q4 2024, an estimated $19.4K.
  • Coppell Advisory Solutions first reported a position in Immunocore in Q3 2024 and held it in 1 quarter.
  • Coppell Advisory Solutions's Immunocore position peaked at $19.4K in Q3 2024.
  • 115 funds tracked by Wall St. Rank held Immunocore as of Q4 2024.

Based on Coppell Advisory Solutions's 13F filing for Q4 2024, filed 14 Feb 2025.